Vera Therapeutics (Nasdaq:VERA) - Cotización, noticias y análisis

Resumen de acción VERA

Vera Therapeutics, Inc. es una empresa de biotecnología en fase clínica centrada en el desarrollo y la comercialización de tratamientos para pacientes con enfermedades inmunológicas graves. Saber más

Análisis fundamental de VERA
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Cotiza un 88.7% por debajo de nuestra estimación de su valor justo

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Competidores de Vera Therapeutics, Inc.

VitaSpring Biomedical

OTCPK:VSBC

US$3.1b

Dyne Therapeutics

NasdaqGS:DYN

US$3.1b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Xenon Pharmaceuticals

NasdaqGM:XENE

US$3.0b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Vera Therapeutics
Precios históricos de las acciones
Precio actual de la acción	US$47.03
Máximo en las últimas 52 semanas	US$51.61
Mínimo de 52 semanas	US$12.28
Beta	1.02
1Cambio en 1 mes	15.52%
Variación en 3 meses	19.67%
Cambio de 1 año	257.37%
3Variación en 3 años	77.47%
Variación en 5 años	n/a
Variación desde la OPV	308.96%

Noticias y actualizaciones recientes

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Rentabilidad de los accionistas

	VERA	US Biotechs	Mercado US
7D	-4.0%	-3.7%	0.3%
1Y	257.4%	15.2%	31.1%

Rentabilidad vs. Industria: VERA superó a la industria US Biotechs, que obtuvo un rendimiento del 15.2% el año pasado.

Rentabilidad vs. Mercado: VERA superó al mercado US, que obtuvo un rendimiento del 31.1% el año pasado.

Volatilidad de los precios

Is VERA's price volatile compared to industry and market?
VERA volatility
VERA Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: VERA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VERA (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	82	Marshall Fordyce	veratx.com

Vera Therapeutics, Inc, empresa de biotecnología en fase clínica, se centra en el desarrollo y la comercialización de tratamientos para pacientes con enfermedades inmunológicas graves. Su principal producto candidato es el atacicept, una proteína de fusión autoadministrada en forma de inyección subcutánea que está en fase III de ensayo clínico para pacientes con nefropatía por inmunoglobulina A; y para el tratamiento de la nefritis lúpica que está en fase II de ensayo clínico. También está desarrollando MAU868, un anticuerpo monoclonal humano para el tratamiento de infecciones por viremia BK.

Resumen de fundamentos de Vera Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Vera Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de VERA
Capitalización bursátil	US$2.90b
Beneficios(TTM)	-US$134.38m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-22.2x

Ratio precio-beneficio (PE)

¿Está VERA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VERA
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$134.38m
Beneficios	-US$134.38m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.12
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	17.5%

¿Cómo se ha desempeñado VERA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción VERA

Recompensas

Análisis de riesgos

Competidores de Vera Therapeutics, Inc.

OTCPK:VSBC

US$3.1b

NasdaqGS:DYN

US$3.1b

NasdaqGS:AGIO

US$3.1b

NasdaqGM:XENE

US$3.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Recent updates

Vera Therapeutics, Inc. Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors